DNA damage response - A double-edged sword in cancer prevention and cancer therapy

Cancer Letters

Volumn 358, Issue 1, 2015, Pages 8-16

  Tian, Hui ^a   Gao, Zhen ^a   Li, HuiZhong ^a   Zhang, BaoFu ^a   Wang, Gang ^a   Zhang, Qing ^a   Pei, DongSheng ^a   Zheng, JunNian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cancer prevention; Cancer therapy; DNA damage response; Genomic instability; Sensitization

Indexed keywords

APOPTOSIS; CANCER PREVENTION; CANCER RECURRENCE; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DNA SYNTHESIS; DOWN REGULATION; EXCISION REPAIR; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; MALIGNANT TRANSFORMATION; MISMATCH REPAIR; ONCOGENE; RECOMBINATION REPAIR; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSLESION DNA SYNTHESIS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; CELL CYCLE CHECKPOINT; GENETICS; GERMLINE MUTATION; MOLECULARLY TARGETED THERAPY; NEOPLASMS;

APOPTOSIS; CELL CYCLE CHECKPOINTS; DNA DAMAGE; DNA REPAIR; GENOMIC INSTABILITY; GERM-LINE MUTATION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84921299978     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.038     Document Type: Review

References (82)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature 1998, 396:643-649.
3. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
4. Wyman C., Kanaar R. DNA double-strand break repair: all's well that ends well. Annu. Rev. Genet 2006, 40:363-383.
5. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
6. Mills K.D., Ferguson D.O., Alt F.W. The role of DNA breaks in genomic instability and tumorigenesis. Immunol. Rev 2003, 194:77-95.
7. Jackson S.P., Bartek J. The DNA-damage response in human biology and disease. Nature 2009, 461:1071-1078.
8. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet 2001, 27:247-254.
9. Deans A.J., West S.C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 2011, 11:467-480.
10. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56:3087-3090.
11. Trivedi R.N., Almeida K.H., Fornsaglio J.L., Schamus S., Sobol R.W. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005, 65:6394-6400.
12. Harfe B.D., Jinks-Robertson S. DNA mismatch repair and genetic instability. Annu. Rev. Genet 2000, 34:359-399.
13. Fink D., Aebi S., Howell S.B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res 1998, 4:1-6.
14. Tornaletti S., Hanawalt P.C. Effect of DNA lesions on transcription elongation. Biochimie 1999, 81:139-146.
15. Hanawalt P.C. Subpathways of nucleotide excision repair and their regulation. Oncogene 2002, 21:8949-8956.
16. Yamashita Y.M., Okada T., Matsusaka T., Sonoda E., Zhao G.Y., Araki K., et al. RAD18 and RAD54 cooperatively contribute to maintenance of genomic stability in vertebrate cells. EMBO J. 2002, 21:5558-5566.
17. O-Wang J., Kawamura K., Tada Y., Ohmori H., Kimura H., Sakiyama S., et al. DNA polymerase kappa, implicated in spontaneous and DNA damage-induced mutagenesis, is overexpressed in lung cancer. Cancer Res 2001, 61:5366-5369.
18. Boudsocq F., Benaim P., Canitrot Y., Knibiehler M., Ausseil F., Capp J.P., et al. Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase beta. Mol. Pharmacol 2005, 67:1485-1492.
19. Lieber M.R., Ma Y., Pannicke U., Schwarz K. Mechanism and regulation of human non-homologous DNA end-joining. Nat. Rev. Mol. Cell Biol 2003, 4:712-720.
20. Walker J.R., Corpina R.A., Goldberg J. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 2001, 412:607-614.
21. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
22. Paull T.T., Cortez D., Bowers B., Elledge S.J., Gellert M. Direct DNA binding by Brca1. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6086-6091.
23. Yang H., Jeffrey P.D., Miller J., Kinnucan E., Sun Y., Thoma N.H., et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 2002, 297:1837-1848.
24. Powell S.N., Kachnic L.A. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003, 22:5784-5791.
25. D'Andrea A.D., Grompe M. The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer 2003, 3:23-34.
26. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet 2007, 8:735-748.
27. Kennedy R.D., D'Andrea A.D. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005, 19:2925-2940.
28. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 2001, 7:249-262.
29. Meetei A.R., de Winter J.P., Medhurst A.L., Wallisch M., Waisfisz Q., van de Vrugt H.J., et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat. Genet 2003, 35:165-170.
30. Cole A.R., Lewis L.P., Walden H. The structure of the catalytic subunit FANCL of the Fanconi anemia core complex. Nat. Struct. Mol. Biol 2010, 17:294-298.
31. Garner E., Smogorzewska A. Ubiquitylation and the Fanconi anemia pathway. FEBS Lett 2011, 585:2853-2860.
32. Nakanishi K., Yang Y.G., Pierce A.J., Taniguchi T., Digweed M., D'Andrea A.D., et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1110-1115.
33. Nakanishi K., Cavallo F., Perrouault L., Giovannangeli C., Moynahan M.E., Barchi M., et al. Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication. Nat. Struct. Mol. Biol 2011, 18:500-503.
34. Nijman S.M., Huang T.T., Dirac A.M., Brummelkamp T.R., Kerkhoven R.M., D'Andrea A.D., et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 2005, 17:331-339.
35. Murai J., Yang K., Dejsuphong D., Hirota K., Takeda S., D'Andrea A.D. The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Mol. Cell. Biol 2011, 31:2462-2469.
36. Kutler D.I., Auerbach A.D., Satagopan J., Giampietro P.F., Batish S.D., Huvos A.G., et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. Head Neck Surg 2003, 129:106-112.
37. Cheng Q., Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 2010, 9:472-478.
38. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995, 55:5187-5190.
39. Shapiro G.I., Harper J.W. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest 1999, 104:1645-1653.
40. Lehmann A.R. DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie 2003, 85:1101-1111.
41. Reynolds T.Y., Rockwell S., Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res 1996, 56:5754-5757.
42. Yuan J., Narayanan L., Rockwell S., Glazer P.M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 2000, 60:4372-4376.
43. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol 2006, 1:119-150.
44. Mihaylova V.T., Bindra R.S., Yuan J., Campisi D., Narayanan L., Jensen R., et al. Decreased expression of the DNA mismatch repair gene Mlh1 under hypoxic stress in mammalian cells. Mol. Cell. Biol 2003, 23:3265-3273.
45. Koshiji M., To K.K., Hammer S., Kumamoto K., Harris A.L., Modrich P., et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell 2005, 17:793-803.
46. Bindra R.S., Gibson S.L., Meng A., Westermark U., Jasin M., Pierce A.J., et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005, 65:11597-11604.
47. Ren B., Cam H., Takahashi Y., Volkert T., Terragni J., Young R.A., et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 2002, 16:245-256.
48. Bindra R.S., Glazer P.M. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 2007, 26:2048-2057.
49. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
50. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
51. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med 2005, 352:987-996.
52. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
53. Dungey F.A., Loser D.A., Chalmers A.J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys 2008, 72:1188-1197.
54. Volk R.B., Girreser U., Al-Refai M., Laatsch H. Bromoanaindolone, a novel antimicrobial exometabolite from the cyanobacterium Anabaena constricta. Nat. Prod. Res 2009, 23:607-612.
55. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995, 268:1749-1753.
56. Sarkaria J.N., Busby E.C., Tibbetts R.S., Roos P., Taya Y., Karnitz L.M., et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999, 59:4375-4382.
57. Sabisz M., Skladanowski A. Modulation of cellular response to anticancer treatment by caffeine: inhibition of cell cycle checkpoints, DNA repair and more. Curr. Pharm. Biotechnol 2008, 9:325-336.
58. Hickson I., Zhao Y., Richardson C.J., Green S.J., Martin N.M., Orr A.I., et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004, 64:9152-9159.
59. Janetka J.W., Ashwell S., Zabludoff S., Lyne P. Inhibitors of checkpoint kinases: from discovery to the clinic. Curr. Opin. Drug Discov. Devel 2007, 10:473-486.
60. Bartek J., Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3:421-429.
61. Graves P.R., Yu L., Schwarz J.K., Gales J., Sausville E.A., O'Connor P.M., et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem 2000, 275:5600-5605.
62. Welch S., Hirte H.W., Carey M.S., Hotte S.J., Tsao M.S., Brown S., et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol. Oncol 2007, 106:305-310.
63. Tse A.N., Carvajal R., Schwartz G.K. Targeting checkpoint kinase 1 in cancer therapeutics. Clin. Cancer Res 2007, 13:1955-1960.
64. Fan S., Smith M.L., Rivet D.J., Duba D., Zhan Q., Kohn K.W., et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995, 55:1649-1654.
65. Pirollo K.F., Hao Z., Rait A., Jang Y.J., Fee W.E., Ryan P., et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997, 14:1735-1746.
66. Shatrov V.A., Ameyar M., Bouquet C., Cai Z., Stancou R., Haddada H., et al. Adenovirus-mediated wild-type-p53-gene expression sensitizes TNF-resistant tumor cells to TNF-induced cytotoxicity by altering the cellular redox state. Int. J. Cancer 2000, 85:93-97.
67. Gibson A.A., Harwood F.G., Tillman D.M., Houghton J.A. Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression. Clin. Cancer Res 1998, 4:145-152.
68. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M.S., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet 2004, 13:2443-2449.
69. Taniguchi T., Garcia-Higuera I., Andreassen P.R., Gregory R.C., Grompe M., D'Andrea A.D. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood 2002, 100:2414-2420.
70. van der Heijden M.S., Brody J.R., Dezentje D.A., Gallmeier E., Cunningham S.C., Swartz M.J., et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin. Cancer Res 2005, 11:7508-7515.
71. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med 1997, 3:730-737.
72. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
73. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514.
74. Hambardzumyan D., Becher O.J., Rosenblum M.K., Pandolfi P.P., Manova-Todorova K., Holland E.C. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008, 22:436-448.
75. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
76. McCord A.M., Jamal M., Williams E.S., Camphausen K., Tofilon P.J. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin. Cancer Res 2009, 15:5145-5153.
77. Kao G.D., Jiang Z., Fernandes A.M., Gupta A.K., Maity A. Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation. J. Biol. Chem 2007, 282:21206-21212.
78. Dai Y., Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res 2010, 16:376-383.
79. Taylor R.A., Risbridger G.P. Prostatic tumor stroma: a key player in cancer progression. Curr. Cancer Drug Targets 2008, 8:490-497.
80. Li Z., Bao S., Wu Q., Wang H., Eyler C., Sathornsumetee S., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513.
81. Hjelmeland A.B., Wu Q., Heddleston J.M., Choudhary G.S., MacSwords J., Lathia J.D., et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 2011, 18:829-840.
82. Davis I.D., Desai J. Clinical use of therapies targeting tumor vasculature and stroma. Curr. Cancer Drug Targets 2008, 8:498-508.